These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320 [TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
9. Performance evaluation of Bruker UMIC Bianco G; Boattini M; Comini S; Gaibani P; Cavallo R; Costa C Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):559-566. PubMed ID: 38240988 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal. Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019). Takemura M; Wise MG; Hackel MA; Sahm DF; Yamano Y J Antimicrob Chemother; 2023 Aug; 78(8):2019-2027. PubMed ID: 37390312 [TBL] [Abstract][Full Text] [Related]
13. Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F; Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963 [TBL] [Abstract][Full Text] [Related]
14. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium. Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010 [TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. El Ghali A; Kunz Coyne AJ; Lucas K; Tieman M; Xhemali X; Lau S-p; Iturralde G; Purdy A; Holger DJ; Garcia E; Veve MP; Rybak MJ Microbiol Spectr; 2024 Feb; 12(2):e0310823. PubMed ID: 38206034 [TBL] [Abstract][Full Text] [Related]
17. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018. Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792 [TBL] [Abstract][Full Text] [Related]
20. Activity of Cefiderocol Against Iregui A; Khan Z; Landman D; Quale J Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]